Vanda Pharmaceuticals Inc (VNDA)
4.075
+0.02
(+0.37%)
USD |
NASDAQ |
Apr 16, 11:43
Vanda Pharmaceuticals Enterprise Value: -154.66M for April 15, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 15, 2024 | -154.66M |
| April 12, 2024 | -151.21M |
| April 11, 2024 | -142.00M |
| April 10, 2024 | -142.00M |
| April 09, 2024 | -137.40M |
| April 08, 2024 | -128.77M |
| April 05, 2024 | -110.93M |
| April 04, 2024 | -105.18M |
| April 03, 2024 | -97.70M |
| April 02, 2024 | -163.29M |
| April 01, 2024 | -151.21M |
| March 28, 2024 | -151.78M |
| March 27, 2024 | -164.44M |
| March 26, 2024 | -166.17M |
| March 25, 2024 | -165.59M |
| March 22, 2024 | -164.44M |
| March 21, 2024 | -163.29M |
| March 20, 2024 | -169.62M |
| March 19, 2024 | -171.92M |
| March 18, 2024 | -172.50M |
| March 15, 2024 | -169.05M |
| March 14, 2024 | -169.62M |
| March 13, 2024 | -167.32M |
| March 12, 2024 | -165.02M |
| March 11, 2024 | -157.83M |
| Date | Value |
|---|---|
| March 08, 2024 | -165.59M |
| March 07, 2024 | -168.47M |
| March 06, 2024 | -163.29M |
| March 05, 2024 | -150.06M |
| March 04, 2024 | -142.58M |
| March 01, 2024 | -123.02M |
| February 29, 2024 | -131.07M |
| February 28, 2024 | -131.07M |
| February 27, 2024 | -124.17M |
| February 26, 2024 | -125.89M |
| February 23, 2024 | -132.22M |
| February 22, 2024 | -139.13M |
| February 21, 2024 | -138.55M |
| February 20, 2024 | -137.98M |
| February 16, 2024 | -136.25M |
| February 15, 2024 | -136.83M |
| February 14, 2024 | -143.73M |
| February 13, 2024 | -154.66M |
| February 12, 2024 | -139.13M |
| February 09, 2024 | -148.91M |
| February 08, 2024 | -154.09M |
| February 07, 2024 | -178.83M |
| February 06, 2024 | -173.65M |
| February 05, 2024 | -188.61M |
| February 02, 2024 | -179.40M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-295.40M
Minimum
Nov 09 2023
800.06M
Maximum
Jun 30 2021
244.24M
Average
273.05M
Median
Enterprise Value Benchmarks
| ADMA Biologics Inc | 1.444B |
| Johnson & Johnson | 361.91B |
| Nektar Therapeutics | -15.34M |
| Invivyd Inc | 134.37M |
| Amicus Therapeutics Inc | 3.250B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.40M |
| Revenue (Quarterly) | 45.27M |
| Total Expenses (Quarterly) | 52.36M |
| EPS Diluted (Quarterly) | -0.04 |
| Gross Profit Margin (Quarterly) | 92.36% |
| Profit Margin (Quarterly) | -5.30% |
| Earnings Yield | 1.29% |
| Normalized Earnings Yield | 1.285 |